“…By investigating the clinical course of 31 heavily pretreated patients with r/r MM receiving VTd-PACE and PACE-M as salvage therapy, we observed an ORR of 71% which is in line with previously reported ORR of 67.7%, 68.4%, 73%, 75%, and 77% [ 8 , 10 , 11 , 26 , 27 ] and is significantly higher than the lately described ORR of 20% to the next applied therapy for triple-class exposed patients [ 4 ]. Usually, complete responses only account for a minor part of the ORR reported for VTd-PACE or PACE-M with 0–14% [ 7 – 11 , 13 , 27 – 29 ]. Thus, we do not consider the lack of complete responses in our study population as unusual, as bone marrow evaluations for response documentation were not performed routinely in clinical practice, but see our results in line with previously reported data of most retrospective studies [ 5 , 7 , 9 , 12 , 13 , 28 ].…”